Table of Contents Author Guidelines Submit a Manuscript
Cardiology Research and Practice
Volume 2012, Article ID 925046, 10 pages
http://dx.doi.org/10.1155/2012/925046
Clinical Study

Hypertension Control and Cardiometabolic Risk: A Regional Perspective

1Institute for Clinical Pharmacology, Medical Faculty Carl Gustav Carus, Technical University Dresden, 01307 Dresden, Germany
2Léman Research Institute GmbH, 6300 Zug, Switzerland
3Institute for Cardiovascular Pharmacology and Epidemiology, 15831 Mahlow, Germany
4Medical Affairs Department, Sanofi, Shanghai 200000, China
5Cardiology Division and Hypertension Unit, S. Andrea Hospital, La Sapienza University of Rome, 00189 Rome, Italy
6I. R. C. C. S. Neuromed, 86077 Pozzili, Italy
7Medical Affairs Department, Sanofi-Aventis (Suisse) SA, 1217 Meyrin, Switzerland

Received 11 August 2011; Accepted 1 November 2011

Academic Editor: Bobby Varkey Khan

Copyright © 2012 Martin Thoenes et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. D. Lopez, C. D. Mathers, M. Ezzati, D. T. Jamison, and C. J. Murray, “Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data,” Lancet, vol. 367, no. 9524, pp. 1747–1757, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. P. M. Kearney, M. Whelton, K. Reynolds, P. Muntner, P. K. Whelton, and J. He, “Global burden of hypertension: analysis of worldwide data,” Lancet, vol. 365, no. 9455, pp. 217–223, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Bramlage, M. Böhm, M. Volpe et al., “A global perspective on blood pressure treatment and control in a referred cohort of hypertensive patients,” Journal of Clinical Hypertension, vol. 12, no. 9, pp. 666–677, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Whitlock, S. Lewington, P. Sherliker, R. Clarke, J. Emberson, and J. Halsey, “Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies,” The Lancet, vol. 373, no. 9669, pp. 1083–1096, 2009. View at Publisher · View at Google Scholar
  5. J. St-Pierre, I. Lemieux, P. Perron et al., “Relation of the “hypertriglyceridemic waist” phenotype to earlier manifestations of coronary artery disease in patients with glucose intolerance and type 2 diabetes mellitus,” American Journal of Cardiology, vol. 99, no. 3, pp. 369–373, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. V. Manninen, L. Tenkanen, P. Koskinen et al., “Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment,” Circulation, vol. 85, no. 1, pp. 37–45, 1992. View at Google Scholar · View at Scopus
  7. C. Nielson, T. Lange, and N. Hadjokas, “Blood glucose and coronary artery disease in nondiabetic patients,” Diabetes Care, vol. 29, no. 5, pp. 998–1001, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. “2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension,” Journal of Hypertension, vol. 21, no. 6, pp. 1011–1153, 2003.
  9. A. M. Kuklinska, B. Mroczko, W. J. Musial et al., “Influence of atorvastatin on blood pressure control in treated hypertensive, normolipemic patients. An open, pilot study,” Blood Pressure, vol. 19, no. 4, pp. 260–266, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Hansel, X. Girerd, D. Bonnefont-Rousselot et al., “Blood pressure-lowering response to amlodipine as a determinant of the antioxidative activity of small, dense HDL3,” American Journal of Cardiovascular Drugs, vol. 11, no. 5, pp. 317–325, 2011. View at Publisher · View at Google Scholar
  11. M. Böhm, M. Thoenes, N. Danchin, P. Bramlage, P. La Puerta, and M. Volpe, “Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the i-SEARCH global study,” Journal of Hypertension, vol. 25, no. 11, pp. 2317–2324, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. D. A. Belletti, C. Zacker, and J. Wogen, “Effect of cardiometabolic risk factors on hypertension management: a cross-sectional study among 28 physician practices in the United States,” Cardiovascular Diabetology, vol. 9, article 7, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Farsang, L. Naditch-Brule, S. Perlini, W. Zidek, and S. E. Kjeldsen, “Inter-regional comparisons of the prevalence of cardiometabolic risk factors in patients with hypertension in Europe: the GOOD survey,” Journal of Human Hypertension, vol. 23, no. 5, pp. 316–324, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. S. E. Kjeldsen, L. Naditch-Brule, S. Perlini, W. Zidek, and C. Farsang, “Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardiometabolic Risk Profile in Patients with hypertension disease survey,” Journal of Hypertension, vol. 26, no. 10, pp. 2064–2070, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. J. P. Després, “Intra-abdominal obesity: an untreated risk factor for Type 2 diabetes and cardiovascular disease,” Journal of endocrinological investigation., vol. 29, no. 3, supplement, pp. 77–82, 2006. View at Google Scholar
  16. G. de Simone, M. H. Olsen, K. Wachtell et al., “Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study,” Journal of Human Hypertension, vol. 21, no. 8, pp. 625–632, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. J. M. Torpy, C. Lynm, and R. M. Glass, “JAMA patient page. The metabolic syndrome,” Journal of the American Medical Association, vol. 295, no. 7, p. 850, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. W. Zidek, L. Naditch-Brûlé, S. Perlini, C. Farsang, and S. E. Kjeldsen, “Blood pressure control and components of the metabolic syndrome: The good survey,” Cardiovascular Diabetology, vol. 8, article 51, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. M. A. E. Anna Diehl, “Nonalcoholic steatosis and steatohepatitis IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines,” American Journal of Physiology, vol. 282, no. 1, pp. G1–G5, 2002. View at Google Scholar · View at Scopus
  20. S. M. Grundy, “Inflammation hypertension, and the metabolic syndrome,” Journal of the American Medical Association, vol. 290, no. 22, pp. 3000–3002, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. K. J. Greenlunda, M. L. Daviglus, and J. B. Croft, “Differences in healthy lifestyle characteristics between adults with prehypertension and normal blood pressure,” Journal of Hypertension, vol. 27, no. 5, pp. 955–962, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. N. T. Nguyen, C. P. Magno, K. T. Lane, M. W. Hinojosa, and J. S. Lane, “Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the national health and nutrition examination survey, 1999 to 2004,” Journal of the American College of Surgeons, vol. 207, no. 6, pp. 928–934, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Farsang, L. Naditch-Brule, A. Avogaro et al., “Where are we with the management of hypertension? From science to clinical practice,” Journal of Clinical Hypertension, vol. 11, no. 2, pp. 66–73, 2009. View at Publisher · View at Google Scholar